In 2023, the Alimentary Tract and Metabolism Medicine sales in Japan were measured at $39.6 per capita. Forecasts for 2024 to 2028 show a modest annual growth, with values reaching $40.2 per capita by 2028. This represents a year-on-year increase of around 0.25% to 0.50%, with a compound annual growth rate (CAGR) of approximately 0.55% over the five-year period.

Future trends to watch for include:

Increasing emphasis on personalized medicine owing to technological advances, impacting product offerings and sales.
Aging population in Japan may drive demand for gastrointestinal and metabolic treatments.
Potential changes in healthcare policies affecting pricing and accessibility of medication.